150 related articles for article (PubMed ID: 38656630)
1. Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis.
Wakabayashi N; Watanabe S; Abe T; Takenaka J; Hirata K; Kimura R; Sakamoto K; Shinohara N; Kudo K
Ann Nucl Med; 2024 Apr; ():. PubMed ID: 38656630
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical trial for [
Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of [
Takenaka J; Watanabe S; Abe T; Hirata K; Uchiyama Y; Kimura R; Shinohara N; Kudo K
Ann Nucl Med; 2023 Jan; 37(1):10-17. PubMed ID: 36301465
[TBL] [Abstract][Full Text] [Related]
5. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [
Inaki A; Shiga T; Tsushima Y; Jinguji M; Wakabayashi H; Kayano D; Akatani N; Yamase T; Kunita Y; Watanabe S; Hiromasa T; Mori H; Hirata K; Watanabe S; Higuchi T; Tomonaga H; Kinuya S
Ann Nucl Med; 2022 Mar; 36(3):267-278. PubMed ID: 34870794
[TBL] [Abstract][Full Text] [Related]
6. A phase I clinical trial for [
Wakabayashi H; Inaki A; Yoshimura K; Murayama T; Imai Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
Sci Rep; 2019 May; 9(1):7625. PubMed ID: 31110198
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of High-Specific-Activity
Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
[TBL] [Abstract][Full Text] [Related]
8. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
9. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
10. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'.
Satapathy S; Mittal BR; Bhansali A
Clin Endocrinol (Oxf); 2019 Dec; 91(6):718-727. PubMed ID: 31569282
[TBL] [Abstract][Full Text] [Related]
11. 131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study.
Kotecka-Blicharz A; Hasse-Lazar K; Handkiewicz-Junak D; Gawlik T; Pawlaczek A; Oczko-Wojciechowska M; Michalik B; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2018; 69(3):246-251. PubMed ID: 29645065
[TBL] [Abstract][Full Text] [Related]
12. Low-dose (123)I-metaiodobenzylguanidine diagnostic scan is inferior to (131)I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma.
Kayano D; Taki J; Fukuoka M; Wakabayashi H; Inaki A; Nakamura A; Kinuya S
Nucl Med Commun; 2011 Oct; 32(10):941-6. PubMed ID: 21876405
[TBL] [Abstract][Full Text] [Related]
13. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
14. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of
Maric I; Weber M; Prochnow A; Schmitz J; Unger N; Schaarschmidt BM; Poeppel TD; Rischpler C; Bockisch A; Herrmann K; Jentzen W; Fendler WP
J Nucl Med; 2023 Jun; 64(6):885-891. PubMed ID: 36732054
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of early FDG-PET response to [131I] MIBG treatment for unresectable or metastatic pheochromocytomas and paragangliomas (PPGLs).
Takenaka J; Watanabe S; Abe T; Tsuchikawa T; Takeuchi S; Hirata K; Kimura R; Wakabayashi N; Shinohara N; Kudo K
Neuroendocrinology; 2023 Sep; ():. PubMed ID: 37725921
[TBL] [Abstract][Full Text] [Related]
17. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
[TBL] [Abstract][Full Text] [Related]
18. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for refractory pheochromocytoma and paraganglioma after
Hiromasa T; Wakabayashi H; Kayano D; Inaki A; Watanabe S; Mori H; Akatani N; Yamase T; Kunita Y; Saito S; Kinuya S
Ann Nucl Med; 2022 Jan; 36(1):61-69. PubMed ID: 34647244
[TBL] [Abstract][Full Text] [Related]
20. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
